Esophageal Sphincter Device for Gastroesophageal Reflux Disease

Robert A. Ganz, M.D., Jeffrey H. Peters, M.D., Santiago Horgan, M.D., Willem A. Bemelman, M.D., Ph.D., Christy M. Dunst, M.D., Steven A. Edmundowicz, M.D., John C. Lipham, M.D., James D. Lucketich, M.D., W. Scott Melvin, M.D., Brant K. Oelschlager, M.D., Steven C. Schlack-Haerer, M.D., C. Daniel Smith, M.D., Christopher C. Smith, M.D., Dan Dunn, M.D., and Paul A. Taiganides, M.D.

From Minnesota Gastroenterology, Plymouth (R.A.G.), and Abbott–Northwestern Hospital, Minneapolis (D.D.) — both in Minnesota; the Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, NY (J.H.P.); the Department of Surgery, University of California, San Diego, La Jolla (S.H.), and the Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles (J.C.L.) — both in California; the Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam (W.A.B.); the Gastrointestinal and Minimally Invasive Surgery Division, Oregon Clinic, Portland (C.M.D.); the Division of Gastroenterology, Mayo Clinic–Florida, Jacksonville (W.A.B.); the Department of Thoracic Surgery, University of Pittsburgh, Pittsburgh (J.D.L.); the Department of Surgery, Ohio State University, Columbus (W.S.M.), and Knox Regional Heartburn Treatment Center, Mount Vernon (P.A.T.) — both in Ohio; the Department of Gastroenterology, Washington University School of Medicine, St. Louis (S.A.E.); the Division of Thoracic Surgery, University of Pittsburgh, Pittsburgh (J.D.L.); the Department of Surgery, Ohio State University, Columbus (W.S.M.), and Knox Regional Heartburn Treatment Center, Mount Vernon (P.A.T.) — both in Ohio; the Department of Gastroenterology, Gundersen Lutheran Medical Center, La Crosse, WI (S.C.S.-H.); the Department of Surgery, Mayo Clinic–Florida, Jacksonville (C.D.S.); and Southern Reflux Center at Albany Surgical Center, Albany, GA (C.C.S.). Address reprint requests to Dr. Ganz at Minnesota Gastroenterology, 15700 37th Ave. N., Suite 300, Plymouth, MN 55446.

Copyright © 2013 Massachusetts Medical Society.

ABSTRACT

BACKGROUND
Patients with gastroesophageal reflux disease who have a partial response to proton-pump inhibitors often seek alternative therapy. We evaluated the safety and effectiveness of a new magnetic device to augment the lower esophageal sphincter.

METHODS
We prospectively assessed 100 patients with gastroesophageal reflux disease before and after sphincter augmentation. The study did not include a concurrent control group. The primary outcome measure was normalization of esophageal acid exposure or a 50% or greater reduction in exposure at 1 year. Secondary outcomes were 50% or greater improvement in quality of life related to gastroesophageal reflux disease and a 50% or greater reduction in the use of proton-pump inhibitors at 1 year. For each outcome, the prespecified definition of successful treatment was achievement of the outcome in at least 60% of the patients. The 3-year results of a 5-year study are reported.

RESULTS
The primary outcome was achieved in 64% of patients (95% confidence interval [CI], 54 to 73). For the secondary outcomes, a reduction of 50% or more in the use of proton-pump inhibitors occurred in 93% of patients, and there was improvement of 50% or more in quality-of-life scores in 92%, as compared with scores for patients assessed at baseline while they were not taking proton-pump inhibitors. The most frequent adverse event was dysphagia (in 68% of patients postoperatively, in 11% at 1 year, and in 4% at 3 years). Serious adverse events occurred in six patients, and in six patients the device was removed.

CONCLUSIONS
In this single-group evaluation of 100 patients before and after sphincter augmentation with a magnetic device, exposure to esophageal acid decreased, reflux symptoms improved, and use of proton-pump inhibitors decreased. Follow-up studies are needed to assess long-term safety. (Funded by Torax Medical; ClinicalTrials.gov number, NCT00776997.)
The fundamental pathologic abnormality in gastroesophageal reflux disease is an incompetent lower esophageal sphincter.\textsuperscript{1-3} First-line therapy for gastroesophageal reflux disease is acid suppression, usually with proton-pump inhibitors. Although effective, proton-pump inhibitors provide incomplete control of reflux symptoms in up to 40% of patients.\textsuperscript{4-6} A partial response can occur because these drugs do not address an incompetent sphincter or prevent reflux; consequently, some patients have only partial relief from symptoms and seek alternative treatment if their quality of life is compromised. At present, the only established option for these patients is antireflux surgery, typically Nissen fundoplication. However, the acceptance of surgery is limited, owing to potential side effects, such as abdominal bloating, increased flatulence, inability to belch or vomit, and persistent dysphagia.\textsuperscript{7,8}

Augmentation of the esophageal sphincter with a magnetic device may provide an alternative treatment for patients who have incomplete symptom relief with proton-pump inhibitors or who are reluctant to undergo surgical fundoplication.\textsuperscript{9-11} The aim of magnetic sphincter augmentation is to improve the barrier function of the sphincter without altering the hiatal and gastric anatomy or interfering with swallowing, belching, or vomiting. The feasibility of this concept was shown in a pilot study.\textsuperscript{11} We report the 3-year outcomes of a 5-year clinical trial assessing the safety and effectiveness of a magnetic device for sphincter augmentation.

**METHODS**

**STUDY DESIGN**

The study was designed by the sponsor (Torax Medical), the investigators, and the Food and Drug Administration as a 5-year prospective, multicenter, single-group evaluation of a magnetic sphincter device. There was no concurrent control group. The primary objective of the study was to evaluate the safety, efficacy, and direct effects of the device on exposure to esophageal acid, quality of life, and use of proton-pump inhibitors.

**PATIENTS**

Between January and September 2009, a total of 13 centers in the United States and 1 in the Netherlands enrolled patients in the study. Eligible patients were 18 to 75 years of age, had at least a 6-month history of reflux disease, and had a partial response to daily proton-pump inhibitors, with increased exposure to esophageal acid as confirmed by pH monitoring. Exclusion criteria were evidence of a large hiatal hernia, esophagitis of grade C or D according to the Los Angeles classification (in which grade A indicates one or more mucosal breaks of ≤5 mm in length, grade B one or more mucosal breaks of >5 mm, grade C mucosal breaks that extend between two or more mucosal folds but involve <75% of the circumference of the esophagus, and grade D mucosal breaks involving ≥75% of the circumference of the esophagus), a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of more than 35, Barrett’s esophagus, a motility disorder, dysphagia more than three times a week, and allergy to titanium, stainless steel, nickel, or ferrous materials. A complete list of inclusion and exclusion criteria is provided in the study protocol, which is available with the full text of this article at NEJM.org.

**STUDY PROCEDURES**

Baseline screening included endoscopy, pH monitoring while the patient was not taking proton-pump inhibitors, barium esophagography, and manometry. These tests, in addition to chest radiography, were repeated 1 year after implantation. Endoscopy and chest radiography were also performed at 2 years and are planned for 5 years. The dose and frequency of proton-pump inhibitors, along with quality of life and foregut symptoms, were evaluated at baseline and postoperatively at 1 week, 3 months, and 6 months and annually starting at 1 year, with plans to continue annual screening for a total of 5 years.

Quality of life was measured with the use of the Gastroesophageal Reflux Disease–Health-Related Quality of Life questionnaire, which is provided in the Supplementary Appendix, available at NEJM.org.\textsuperscript{12} Total scores range from 0 to 50, with higher scores indicating worse symptoms, and no minimally important difference in scores is defined. Quality of life was assessed both while the patient was taking proton-pump inhibitors and while the patient was not taking proton-pump inhibitors at baseline and then while the patient was not taking proton-pump inhibitors at follow-up. Patients were asked about foregut symptoms, such as regurgitation, belching, and vomiting, before and after treatment.\textsuperscript{13} The esophageal sphincter device was implant-
Esophageal Sphincter Device for GERD

Ed with the use of standard laparoscopic techniques by surgeons who had experience with fundoplication. The device involves the use of magnetic attraction through adjacent magnetic beads, which augments the resistance of the esophageal sphincter to abnormal opening associated with reflux.9-11 Each bead contains a sealed core of magnetic neodymium iron boride that produces a precise and permanent force of attraction. The beads are connected to adjacent beads by small wires that allow the device to expand. The device is sized to fit around the external diameter of the esophagus, without compressing the underlying muscle (Fig. 1A). The beads separate with the transport of food or increased intragastric pressure associated with belching or vomiting (Fig. 1B; and see Video 1, available at NEJM.org). There were no dietary restrictions after implantation.

END POINTS

The primary end point was the number of patients who had normalized acid exposure (total proportion of time with a pH of <4 in a 24-hour period, ≤4.5%) or who had a reduction of 50% or more in the proportion of time with a pH of less than 4, as compared with the baseline measurement while the patient was not taking proton-pump inhibitors. The secondary end points, measured separately, were the number of patients with a reduction of 50% or more in the total score for quality of life, as compared with the score at baseline without proton-pump inhibitors, and a reduction of 50% or more in the dose of proton-pump inhibitors, as compared with the baseline dose. All efficacy end points were measured at 1 year, and the treatment was considered to be successful if the efficacy end points were reached in at least 60% of the patients. Safety was monitored throughout the study period, with assessment of the rate and type of serious adverse events related to the device or the implantation procedure.

STUDY OVERSIGHT

The institutional review board of each site approved the study protocol, and written informed consent was obtained from all patients. The data were analyzed by the investigators and the sponsor. A clinical events committee reviewed all adverse events. All the authors vouch for the integrity of the trial and the completeness and accuracy of the reported data and for the fidelity of this report to the study protocol. The first author wrote the initial draft of the manuscript, incorporating revisions from the investigators. The final manuscript was written by a committee consisting of the first author, an investigator, and a physician involved in study oversight, none of whom were employees of the sponsor. All the authors made the decision to submit the manuscript for publication.

STATISTICAL ANALYSIS

All end-point analyses were performed according to the intention-to-treat principle, 1 year after implantation. Patients who did not undergo the end-point evaluation at 1 year or who had missing data were counted as having treatment failure. Additional clinical findings were assessed after 1 year in post hoc analyses of available data. For esophageal acid monitoring, the median pH components at baseline and 1 year after implantation were compared. For quality of life, scores at baseline with and without proton-pump–inhibitor therapy were compared with scores after implantation without proton-pump inhibitors, along with the percentage of patients who said that they were satisfied with their current condition at 1, 2, and 3 years. In addition, the percentage of patients with complete discontinuation of proton-pump inhibitors was assessed at 1, 2, and 3 years.

Continuous demographic characteristics and baseline variables were summarized with the use of standard descriptive statistics (i.e., means with standard deviations and medians with ranges). Categorical demographic characteristics and baseline variables were summarized by means of frequency distributions. A two-tailed, paired Student’s t-test or the Wilcoxon signed-rank test was used to compare values before and after implantation. Differences were considered to be significant at the 0.05 level.

RESULTS

CHARACTERISTICS OF THE PATIENTS

The study population consisted of 100 patients, 52% of whom were men, with a median age of 53 years (range, 18 to 75) and a median BMI of 28 (range, 20 to 35). The median duration of reflux symptoms was 10 years (range, 1 to 40). The median duration of treatment with proton-pump inhibitors was 5 years (range, <1 to 20). Each patient had confirmed increased exposure to esophageal acid while not taking proton-pump inhibitors...
inhibitors (median percentage of time with pH <4 during a median pH-monitoring period of 45 hours, 10.9%; range, 4.8 to 25.4); the median De-Meester score was 36.6 (range, 16.3 to 83.8). The DeMeester score is a composite score of factors quantified during a 24-to-48-hour pH study, with a score of 14.7 or more indicating abnormal reflux. Factors include the percentage of time that the pH was less than 4 during the assessment period, during the time in an upright position, and during the time in a supine position; the total number of reflux episodes; the number of episodes lasting more than 5 minutes; and the duration of the longest episode (in minutes). The
median quality-of-life score was 27 points without proton-pump inhibitors and 11 points with them, indicating a partial response to proton-pump inhibitors. A total of 98 patients completed follow-up at 1 year, 90 at 2 years, and 85 at 3 years. A Consolidated Standards for the Reporting of Trials (CONSORT) diagram is provided in the Supplementary Appendix.

**Surgical Implantation**

The median time required to implant the device (defined as the interval between the placement of the last port and the removal of the first port) was 36 minutes (range, 7 to 125). All the implantations were completed without the need to revert to fundoplication. No intraoperative complications occurred. A total of 51 devices were placed by investigators at academic centers, and 49 by personnel at community-based medical centers. All patients were discharged within 1 day after surgery, with an unrestricted diet.

**Efficacy End Points**

The primary efficacy end point, normalization of or at least a 50% reduction in esophageal acid exposure, was achieved in 64% of patients (64 of 100; 95% confidence interval [CI], 54 to 73). Of the patients who completed pH monitoring, 67% (64 of 96 patients) reached the primary efficacy end point (≥50% reduction in esophageal acid exposure in 64% [61 of 96], and normalization of exposure in 58% [56 of 96]). The secondary efficacy end point, a 50% reduction in the quality-of-life score, as compared with the score without proton-pump–inhibitor therapy at baseline, was achieved in 92% of patients (92 of 100; 95% CI, 85 to 97). In a post hoc analysis, 73% of patients had a reduction of 50% or more in the quality-of-life score at 1 year, as compared with the score with proton-pump–inhibitor therapy at baseline. A reduction of 50% or more in the average daily dose of proton-pump inhibitors occurred in 93% of patients (93 of 100 patients; 95% CI, 86 to 97).

**Additional Analyses**

Post hoc analyses of quality-of-life scores compared changes in the total score and satisfaction level with and without proton-pump–inhibitor therapy. The median total score was 27 points without proton-pump inhibitors and 11 points with proton-pump inhibitors at baseline; the score decreased to 2 at 1 year after implantation (without proton-pump inhibitors) and remained

---

**Figure 2. Quality of Life with Gastroesophageal Reflux Disease.**

Panel A shows the median total score from the Gastroesophageal Reflux Disease–Health Related Quality of Life Scale (the main component of the scale is heartburn; see the Supplementary Appendix) measured at baseline without and with proton-pump inhibitors, as compared with 3 years after implantation, without proton-pump inhibitors. Total scores range from 0 to 50, with higher scores indicating worse symptoms. There was significant improvement in the median score after implantation for all years, as compared with baseline assessments both without and with proton-pump inhibitors (P<0.005 for the three comparisons, by the Wilcoxon signed-rank test). Panel B shows the percentage of patients who reported being satisfied, neutral (neither satisfied nor dissatisfied), or dissatisfied with respect to their present condition, as assessed by means of the Gastroesophageal Reflux Disease–Health Related Quality of Life Scale at baseline with proton-pump inhibitors and at 3 years after implantation and without proton-pump inhibitors. There was significant improvement in the satisfaction level for all 3 years (P<0.001 for the comparison of patients who were satisfied vs. those who were not satisfied or who had a neutral response).
at 2 when assessed at years 2 and 3 (P<0.005 for all three comparisons with baseline) (Fig. 2A). Satisfaction with the reflux condition improved after implantation; 95% of patients reported satisfaction at 1 year, 90% at 2 years, and 94% at 3 years of follow-up, as compared with 13% at baseline (with therapy) (P<0.001 for all three comparisons) (Fig. 2B). There was significant improvement in all the individual pH components after implantation (Table 1). The median percentage of time that the pH was less than 4 while the patient was not receiving proton-pump inhibitors fell from 10.9% before implantation to 3.3% after implantation (P<0.001). Complete cessation of proton-pump inhibitors occurred in 86% of patients (86 of 100 patients) at 1 year, in 87% (78 of 90) at 2 years, and in 87% (72 of 83) at 3 years (P<0.001 for each comparison with patients reporting daily use) (Fig. 2B). Three years after sphincter augmentation, 13% of patients continued to take proton-pump inhibitors; all these patients took the medication at a reduced frequency. The proportion of patients reporting moderate-to-severe regurgitation decreased, from 57% before implantation to 2% at 1 year and to 1% at years 2 and 3 (P<0.001 for all three comparisons with baseline) (Fig. 3B).

SAFETY

Serious adverse events occurred in six patients and required removal of the device in four of the six. In three of the patients, the device was removed at 21, 31, and 93 days after implantation because of persistent dysphagia, with resolution in all three patients after removal, and in one patient, the device was removed at 357 days owing to intermittent vomiting of unknown cause starting 3 months after implantation, without relief after removal. This patient had been rehospitalized at 236 days after implantation for chest pain, nausea, and indigestion that spontaneously resolved. The other two patients who had serious adverse events required rehospitalization for nausea and vomiting 2 days after surgery; their symptoms resolved with conservative therapy. The device was removed in two additional patients as part of their disease management, at 489 days and 1062 days after implantation. One patient had persistent reflux symptoms, and the other had persistent chest pain. Three of the six patients in whom the device was removed subsequently underwent Nissen fundoplication, with no complications.

The most frequent adverse event was dysphagia, which occurred in 68% of patients (Fig. 3C and Table 2). Ongoing dysphagia was noted in 11% of patients at 1 year, in 5% at 2 years, and in 4% at 3 years. Esophageal dilation for dysphagia was allowed at the discretion of the investigator. A total of 19 patients underwent dilation, with 16 reporting improvement after the procedure. The percentage of patients with esophagitis identified

<table>
<thead>
<tr>
<th>Table 1. Components of Esophageal pH Measurements.∞</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Variable</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>pH &lt;4</td>
</tr>
<tr>
<td>Total percentage of time</td>
</tr>
<tr>
<td>Percentage of time upright†</td>
</tr>
<tr>
<td>Percentage of time supine‡</td>
</tr>
<tr>
<td>Total no. of reflux episodes</td>
</tr>
<tr>
<td>No. of reflux episodes lasting &gt;5 min</td>
</tr>
<tr>
<td>Longest reflux episode (min)</td>
</tr>
<tr>
<td>DeMeester score§</td>
</tr>
</tbody>
</table>

* All testing was performed with the use of the Bravo pH monitoring system (Given Imaging) at baseline and at 1 year.
† Time upright was defined as the time during which the patient was not recumbent.
‡ Time supine was defined as the time during which the patient was recumbent.
§ The DeMeester score is a composite score of factors quantified during a 24-to-48-hour pH study, with a score of 14.7 or more indicating abnormal reflux. Factors include the percentage of time that the pH was less than 4 during the total period of assessment, during the time in an upright position, and during the time in a supine position; the total number of reflux episodes; the number of episodes lasting more than 5 minutes; and the duration of the longest episode (in minutes).
at endoscopy decreased to 12% at year 1 and to 11% at year 2, as compared with 40% at baseline (P<0.001 for both comparisons) (Fig. 3D). Among the patients without endoscopic esophagitis at baseline, grade A esophagitis developed in 3 at 1 year and in 4 at 2 years. Grade D esophagitis developed in 1 patient at 1 year; this patient was asymptomatic and therefore did not take proton-pump inhibitors, and reevaluation at 2 years showed complete resolution of esophagitis. Chest radiography and endoscopy performed at 1 year and at 2 years after implantation showed no evidence of device migration or erosion. At 3 years, 2 patients reported an inability to belch or vomit.

**DISCUSSION**

The barrier function of the lower esophageal sphincter depends, in part, on its ability to resist effacement and opening when challenged by gastric distention. Failure to do so results in episodes of gastric juice refluxing into the esoph-
agus, which can injure the esophageal mucosa and underlying muscle, causing permanent damage to the sphincter and leading to further loss of barrier function. Therefore, reducing esophageal exposure to gastric juice is an important goal of antireflux treatment. If reflux is not reduced, symptoms or mucosal injury often persist. Samelson et al. found that a loose ligature placed around the lower esophageal sphincter prevented the sphincter from yielding when challenged by gastric distention. The expandable magnetic device for augmentation of the sphincter builds on this observation by providing greater control of resistance to sphincter effacement and opening than is provided by previous devices, allowing expansion for the passage of food, belching, or vomiting.

Numerous studies have shown that reflux symptoms persist in up to 40% of patients who receive therapy with proton-pump inhibitors and that these symptoms have a negative effect on both quality of life and health care utilization. The results of the current study show that after magnetic sphincter augmentation, quality-of-life scores significantly improved, as compared with preoperative scores without or with proton-pump inhibitors. At 3 years, 87% of patients (72 of 83 patients) had completely eliminated the use of proton-pump inhibitors. These results suggest that sphincter augmentation may be helpful for patients with a partial response to proton-pump inhibitors.

The significant reduction in exposure to esophageal acid provides quantitative evidence that magnetic sphincter augmentation improves the ability of the sphincter to resist the reflux of gastric juice into the esophagus and is associated with sustained control of heartburn and regurgitation. The sustained control of regurgitation implies control of both acid and nonacid reflux. The procedure preserved the ability to belch and vomit in most patients. These outcomes were similar in academic centers and community centers, suggesting that the technique of implanting the device can be standardized. Although these findings are encouraging, we recognize that they are preliminary, given the small study population and the 3-year follow-up.

It has long been recognized that surgical alteration of the lower esophageal sphincter by means of fundoplication may result in dysphagia. Dysphagia also occurs after magnetic sphincter augmentation. In both situations, the postoperative dysphagia is most commonly mild to moderate and resolves with time. Our findings suggest that the risk of dysphagia and need for esophageal dilation after sphincter augmentation is similar to the risk after fundoplication. Most of the patients in our study who underwent dilation had improvement. We speculate that dilation disrupts scarring by actuating the beads, resulting in reduced dysphagia. After sphincter augmentation in this study, persistent dysphagia that led to the removal of the device developed in 3% of patients. This rate of persistent dysphagia is similar to that observed in the pilot study and in registries in the United States and Europe. Removal of the device was required in six patients within 21 days to 2.9 years.

<table>
<thead>
<tr>
<th>Event</th>
<th>Patients (N = 100)</th>
<th>Maximum Level of Intensity*</th>
<th>Device Removal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysphagia</td>
<td>68</td>
<td>Mild 47 Moderate 16 Severe 5</td>
<td>3</td>
</tr>
<tr>
<td>Bloating</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odynophagia</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hicups</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inability to belch or vomit</td>
<td>6</td>
<td>Mild 5 Moderate 1 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>4</td>
<td>Mild 4 Moderate 0 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Flatulence</td>
<td>2</td>
<td>Mild 2 Moderate 0 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Belching</td>
<td>2</td>
<td>Mild 2 Moderate 0 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Weight loss</td>
<td>2</td>
<td>Mild 2 Moderate 0 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Food impaction</td>
<td>1</td>
<td>Mild 0 Moderate 1 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Globus sensation†</td>
<td>1</td>
<td>Mild 1 Moderate 0 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Irritable bowel syndrome or dyspepsia</td>
<td>1</td>
<td>Mild 1 Moderate 0 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Regurgitation of sticky mucus</td>
<td>1</td>
<td>Mild 0 Moderate 1 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Uncomfortable feeling in chest</td>
<td>1</td>
<td>Mild 1 Moderate 0 Severe 0</td>
<td>0</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1</td>
<td>Mild 0 Moderate 1 Severe 0</td>
<td>1</td>
</tr>
<tr>
<td>Persistent GERD symptoms‡</td>
<td>1</td>
<td>Mild 0 Moderate 1 Severe 0</td>
<td>1</td>
</tr>
</tbody>
</table>

* Mild intensity was defined as an awareness of signs or symptoms that did not interfere with usual activities, moderate as discomfort intense enough to cause interference with usual activities, and severe as incapacitating discomfort, with inability to perform work or usual activities.

† The globus sensation is the sensation of having a lump in the throat when no visible abnormality is present on examination.

‡ GERD denotes gastroesophageal reflux disease.
after placement. The possibility of easy removal of the device after a longer interval is unknown.

The placement of a foreign body around a mobile muscular tube such as the esophagus raises concern about erosion and hence the safety of the device. The current study, along with the previously published pilot trial and the commercial registries in the United States and Europe, brings the worldwide clinical experience to 497 magnetic implants, with a median implant duration of 2.9 years. To date, no erosions or migrations have been reported. The risk over a longer period of follow-up is not known. The continued collection of data from the present study, existing registries, and current clinical use will allow assessment of the long-term risk of erosion.

The current study was designed so that the direct effects of the sphincter augmentation device on each patient’s exposure to esophageal acid, use of proton-pump inhibitors, and symptom control could be measured before and after the implantation. This design is limited in that it does not allow direct comparisons with other forms of therapy. Prospective, randomized trials with appropriate controls are needed.

In conclusion, this single-group trial showed that a magnetic device designed to augment the lower esophageal sphincter can be implanted with the use of standard laparoscopic techniques. The device decreased exposure to esophageal acid, improved reflux symptoms, and allowed cessation of proton-pump inhibitors in the majority of patients. Studies with larger samples and longer-term follow-up are needed to confirm these early results and assess longer-term safety.

Supported by Torax Medical. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

REFERENCES


Copyright © 2013 Massachusetts Medical Society.